Frank Morich

Frank M.
Morich is Executive Chairman at Aphaia Pharma AG since 2022.
Dr. Morich is Director at Viewpoint Molecular Targeting, Inc. since 2021.
Dr. Morich is Independent Director at Perspective Therapeutics, Inc. since 2023.
Former roles include Chief Executive Officer & Director at Fujirebio Europe NV from 2005 to 2007, Chief Executive Officer at TME Pharma AG from 2008 to 2010, President & Chief Executive Officer at Takeda A, Deputy Chairman-Supervisory Board at MorphoSys AG from 2015 to 2020, Chairman at Bayer HealthCare AG from 1982 to 2009, Chairman-Executive Board & Chief Executive Officer at AM-Pharma BV, Director at Bayer Corp., Director at Bayer AG from 2000 to 2002, Director & Chief Commercial Officer at Takeda Pharmaceutical Co., Ltd. from 2012 to 2014, Director-Clinical Research at Miles, Inc. from 1982 to 1991, Director at Innate Pharma SA from 2004 to 2010, Director at IsoRay, Inc., Director at Viewpoint (US) from 2021 to 2023, Independent Director at Cue Biopharma, Inc. from 2018 to 2020, Member-Supervisory Board at Neuro3D SA, Executive Vice President-International Operations at Takeda Pharmaceuticals International, Inc. from 2011 to 2012, and Chief Commercial Officer at Takeda Pharmaceuticals International AG from 2011 to 2014.
Education includes a doctorate from Philipps University of Marburg.